Durvalumab
Pharmaceutical drug
Durvalumab
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells. Durvalumab is an immune checkpoint inhibitor drug. It was approved in for medical use in the United States in May 2017, and in the European Union in September 2018.
Read on Wikipedia · Image Fvasconcellos (talk · contribs), Public domain
Open boosters, collect cards and trade them. Free to play.
Play for free